Biomarkers for neurodegenerative diseases
Hansson, Oskar LU
(2021)
In Nature Medicine
27(6).
p.954-963
- Abstract
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic but also to facilitate the development and monitoring of effective disease-modifying therapies. Positron emission tomography methods detecting amyloid-β and tau pathology in Alzheimer’s disease have been increasingly used to improve the design of clinical trials and observational studies. In recent years, easily accessible and cost-effective blood-based biomarkers detecting the same Alzheimer’s disease pathologies have been developed, which might revolutionize the diagnostic workup of Alzheimer’s disease globally. Relevant biomarkers for α-synuclein pathology in Parkinson’s disease are also emerging, as well as blood-based markers of... (More)
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic but also to facilitate the development and monitoring of effective disease-modifying therapies. Positron emission tomography methods detecting amyloid-β and tau pathology in Alzheimer’s disease have been increasingly used to improve the design of clinical trials and observational studies. In recent years, easily accessible and cost-effective blood-based biomarkers detecting the same Alzheimer’s disease pathologies have been developed, which might revolutionize the diagnostic workup of Alzheimer’s disease globally. Relevant biomarkers for α-synuclein pathology in Parkinson’s disease are also emerging, as well as blood-based markers of general neurodegeneration and glial activation. This review presents an overview of the latest advances in the field of biomarkers for neurodegenerative diseases. Future directions are discussed regarding implementation of novel biomarkers in clinical practice and trials.
(Less)
- author
- Hansson, Oskar
LU
- organization
- publishing date
- 2021-06
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nature Medicine
- volume
- 27
- issue
- 6
- pages
- 10 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:34083813
- scopus:85107287933
- ISSN
- 1078-8956
- DOI
- 10.1038/s41591-021-01382-x
- language
- English
- LU publication?
- yes
- id
- f2c911f9-b6fb-44be-807f-f085f438d682
- date added to LUP
- 2021-06-24 13:30:44
- date last changed
- 2024-06-29 14:01:28
@article{f2c911f9-b6fb-44be-807f-f085f438d682,
abstract = {{<p>Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in the clinic but also to facilitate the development and monitoring of effective disease-modifying therapies. Positron emission tomography methods detecting amyloid-β and tau pathology in Alzheimer’s disease have been increasingly used to improve the design of clinical trials and observational studies. In recent years, easily accessible and cost-effective blood-based biomarkers detecting the same Alzheimer’s disease pathologies have been developed, which might revolutionize the diagnostic workup of Alzheimer’s disease globally. Relevant biomarkers for α-synuclein pathology in Parkinson’s disease are also emerging, as well as blood-based markers of general neurodegeneration and glial activation. This review presents an overview of the latest advances in the field of biomarkers for neurodegenerative diseases. Future directions are discussed regarding implementation of novel biomarkers in clinical practice and trials.</p>}},
author = {{Hansson, Oskar}},
issn = {{1078-8956}},
language = {{eng}},
number = {{6}},
pages = {{954--963}},
publisher = {{Nature Publishing Group}},
series = {{Nature Medicine}},
title = {{Biomarkers for neurodegenerative diseases}},
url = {{http://dx.doi.org/10.1038/s41591-021-01382-x}},
doi = {{10.1038/s41591-021-01382-x}},
volume = {{27}},
year = {{2021}},
}